LRMR

Larimar is a pre-revenue, clinical-stage biotech whose entire value rests on one molecule: nomlabofusp, a subcutaneous frataxin-replacement therapy for Friedreich's ataxia. There are no products, no sales in any year shown (FY2021–FY2025 revenue all blank), and losses are accelerating — net loss ballooned to -$166M in FY2025 from -$80.6M in FY2024, with R&D more than doubling (+110.5% to $154M) as the OL study scaled. ROE of -212% and a -$435M accumulated deficit are meaningless as quality signals here; for a development-stage biotech the only fundamentals that matter are cash runway and the clinical/regulatory picture. On that front the MD&A is clear: $136.9M cash at year-end plus $107.6M net raised in February 2026 funds operations only 'into the second quarter of 2027' — a ~1-year cushion that all but guarantees another dilutive raise, on top of the 62% share-count increase already absorbed in FY2025.

The bull case is real but unproven. Nomlabofusp is the first therapy designed to systemically raise FXN — the core deficit in FA — and it carries an unusually strong regulatory stack: FDA Breakthrough Therapy, Fast Track, Orphan Drug and Pediatric Rare Disease designations, EMA PRIME access, UK ILAP and selection into the FDA's START pilot for expedited rare-disease review. Early OL data (14 participants) showed tissue FXN levels rising and holding at day 90 with 'early trends towards improvement in clinical outcomes.' That is the kind of setup that re-rates a $3 stock several-fold on a positive pivotal readout.